TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Pulse assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Screened Participants Who Were Eligible to Participate in the Study
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of Surgeons Agreeing and Adhering to Patient Randomization
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of Randomized Patients Completing the 30-day Postoperative Outcome Assessment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in levels of metabolites of gallic acid in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of eligible subjects who received vaccines
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Time to discontinuation of IV PCA with opioid medication
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Stop-signal task performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Event of Stroke or transient ischemic attack
Endpoint domain: Mortality/survival
Primary endpoint: Event of cardiovascular disease (include stroke/transient ischemic attack)
Endpoint domain: Mortality/survival
Primary endpoint: Knowledge of HIV/STI risks
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: High risk sex/drug behaviors
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: compliance with medications and lifestyle changes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of bladder and/or rectal grade ≥2 toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Eradication status of H. pylori infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change from Baseline in Homeostatic Model Assessment - Beta cell
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change From Baseline in AUCpp
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in SDBG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in MAGE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in Glucose Coefficient of Variation(CV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: clip misfire and misapplication rates
Endpoint domain: Adverse events/effects
Primary endpoint: Alignment of Tibia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Pathologic complete response at surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptomatic Intracerebral Hemorrhage (sICH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Blood Oxygen Dependent (BOLD) functional magnetic resonance imaging (fMRI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Working Memory Performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Basal Forebrain Cholinergic System Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Intelligence outcome
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of Days With Migraine
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Regional Cerebral Oxygenation (rSO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peripheral tissue oxygen saturation (SpO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Non-invasive blood pressure (NIBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MRI and ICD System Related Serious Adverse Device Effect (SADE) Free Rate
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Free of Ventricular Pacing Threshold Rise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Participants Free of R-wave Sensing Attenuation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Level of stress response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Marmara Primary School Readiness Scale
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Prolonged Grief
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction of the M30 antigen in the serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CFTR difference measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-surgical site wound infections
Endpoint domain: Adverse events/effects
Primary endpoint: parastomal hernia rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects presenting with AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Apathy Evaluation Scale (AS) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of cardiovascular death and unplanned admission to hospital for congestive heart failure
Endpoint domain: Mortality/survival
Primary endpoint: Score on Likert Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change of Red blood cells (RBC) count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change of Hemoglobin (Hgb) concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change of Hematocrit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Acne Severity Grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with tumor recurrence and metastasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Initial Comfort Preference
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Appearance Preference
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Diagnostic accuracy of whole-body MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Patient POSAS Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Observer POSAS Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: changes in walked meters on six minute walking test (6MWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of outpatient visits
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: safety outcome
Endpoint domain: Adverse events/effects
Primary endpoint: Lymphocyte reconstitution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Annual Pediatric Health Services Utilization
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in Obesity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Physical inactivity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Subjective Health
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Severe asthma exacerbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percent of heavy-drinking days
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Alcohol problems
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects With Undetectable HCV RNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Exercise frequency
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Incidence of non-serious adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of AEs leading to discontinuation of study treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Hepatic Decompensation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resting Pupil Diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive Style
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: leukocyte telomere length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of subjects with suicidal ideation or suicidal behavior
Endpoint domain: Adverse events/effects
Primary endpoint: Age standardized mortality rates
Endpoint domain: Mortality/survival
Primary endpoint: Number of participants with adverse side effects
Endpoint domain: Adverse events/effects
Primary endpoint: Score of Nutritional Risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Occurrence of different features in the microtubule cytoskeleton
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gut Microbiome alterations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coagulation disorder tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Gene Expression in circulating immune cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Metabolomic profile - Carbohydrates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Stool microbiome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Changes in response conflict in the Stroop Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in the verbal fluency performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Changes in Trail Making A Test performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: BCI Accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall wellbeing of the patients
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in areal bone mineral density of the whole body
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Presence of individual F0 to F4 stage of fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Markers of vascular function associated with exercise capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: TEI index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pharmacokinetic profile of hydrocodone and its metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of study participants that complete the study
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: tolerance of diet and laxative combinations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in habits
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Concentration of Total Gadolinium in Trabecular Bone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of Total Gadolinium in Cortical Bone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wound Closure at Discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Proportion of ETTs in abnormal position
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: 5 year disease-free survival
Endpoint domain: Mortality/survival
Primary endpoint: eVAS Itch
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: eVAS Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in pill burden (the number of statins and PPI's)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Decrease in pill burden (the dose of statins and PPI's)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: simulated ship navigation performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: APOS System effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: categorical score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Volume reduction of upper limb lymphatic edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: subjective intensity and unpleasantness ratings of heat pain tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: objective heat pain tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of Patients Who Recover CD4 Counts Within 6 Months of Completion of Chemotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in PANSS Excited Component (PEC) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pill counts for ARV medications
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in Frequency of Moderate to Severe Hot Flashes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall rate of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Area Under Curve (AUC) of Brief Fatigue Index (BFI)
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Time to Reach the Maximum Observed Analyte Concentration (Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Analyte Concentration-time Curve from Time Zero to 12 Hours (AUC[0-12h])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Motivation for rehabilitation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Treatment related mortality at day 100
Endpoint domain: Mortality/survival
Primary endpoint: Sleep respiratory parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Stride-to-stride variability of stride time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of negative symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of complete ulcer closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biliary duct patency: bilirubin alterations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stent reabsorption: radiographic persistence of stent radiopaque marks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Participants Considered Failures
Endpoint domain: Mortality/survival
Primary endpoint: Vessel Penetration of NICU-Tech RM9L-RS Probe
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Patient resource use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of patients meeting expectations regarding care and treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: plasma citrulline levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: toxicity of Jin Fu Kang / docetaxel combination treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Tolerance of bilevel PAP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Score on Epworth Sleepiness Scale
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Grade III and IV hematologic toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Area Under the Curve (AUCinf) for rosuvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Renal clearance (CLr) for rosuvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Reaction to memory and behavior problems
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: change in serum creatinine level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Dose limit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in calprotectin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of malignancy in pelvic mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of subjects developing Diabetes Mellitus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of time spent in different ranges of ΔPes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proportion of time spent in different ranges of Pmus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proportion of time spent in different ranges of ΔPdi
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change of Period 2 (Per2) protein levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: antigen-specific cell mediated immune responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: stoma rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of patients with at least low grade dysplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Memory Screen Composite Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Participants With Treatment-Emergent Adverse Events (TEAE) During the Treatment Period
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage Change From Baseline to Week 25 in Vital Signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participants With Treatment-emergent Adverse Events (TEAEs) Pertaining to Laboratory Test Values
Endpoint domain: Adverse events/effects
Primary endpoint: Compliance to NPO guideline
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Substance Use Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in clinical laboratory test values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in vital signs measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in electrocardiograms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Patients That Experienced 1 or More Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Success rate of pupal anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic accuracy of thermal imaging for fracture detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in scores on WHODAS 2.0
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Maximum concentration in plasma (Cmax) of Imatinib mesylate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve from zero time until the last measurable concentration (AUClast) of Imatinib mesylate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Cognitive Ability
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Pressure-Specified Sensory Device (PSSD) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire module CIPN20 (EORTC QLQ-CIPN20)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Unified Parkinson's Disease Rating Scale (UPDRS) Motor Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Diagnostic yield of peripheral bronchoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geriatric Oral Health Assessment Index (GOHAI)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of patients maintaining glucose control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of Pancreatic Leakage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Cmax of Dabrafenib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tmax of Dabrafenib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC[0-tau] of Dabrafenib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes